Yvonne Angell, Ph.D.Director and Head of Peptide Chemistry, ChemPartner
Dr. Yvonne M. Angell is the Director and Head of Peptide Chemistry at ChemPartner, where she leads a large peptide chemistry team located in Shanghai, China as well as San Francisco, CA. She drives the peptide therapeutic design and discovery efforts on numerous projects and oversees chemistry operations. Prior to joining ChemPartner, Dr. Angell led research teams and peptide programs across various therapeutic areas at Eli Lilly, Wyeth, Affymax, and Ipsen Bioscience. She has consulted with startup companies to strategize and guide peptide programs through her consulting company, Picotide Technologies. She has advanced many drug discovery programs including five drug candidates into preclinical development, one in the market, and one in phase I clinical trials.
Dr. Angell received her PhD from the University of Wisconsin, Madison, and carried out postdoctoral peptide research as an NIH Fellow at the University of Minnesota, Minneapolis. She is as an inventor on several patents and has numerous scientific publications.
Girish Aakalu, Ph.D.Vice President of Scientific Affairs, Ipsen Bioscience, Inc.
To be added
Richard DiMarchi, Ph.D.Distinguished Professor of Chemistry, Gill Chair in Biomolecular Science, Indiana University
Dr. DiMarchi’s contribution in chemistry and related sciences consists of nearly four decades of work in academics, the pharmaceutical industry and biotechnology. He is a Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University. He is a co-founder of Ambrx, Inc., Marcadia Biotech, Assembly Biosciences, Calibrium and MB2 Biotech. He has served as a scientific advisor to multiple pharmaceutical companies and venture funds. He is currently Chairman of the Peptide Therapeutics Foundation and external board member at Assembly Biosciences.
Dr. DiMarchi is a Vice President at Novo Nordisk Research Laboratories and a retired Group Vice President at Eli Lilly and Company where for more than two decades he provided leadership in biotechnology, endocrine research and product development. He is widely recognized for discovery and development of rDNA-derived Humalog® (LisPro-human insulin), rGlucagon®, and Forteo®. As scientist and executive, Dr. DiMarchi also significantly contributed to the commercial development of Humulin®, Humatrope®, and Evista®. His current research is focused on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization, an approach he has termed chemical-biotechnology. His academic research has broadened the understanding of glucagon physiology while championing the discovery of single molecule mixed agonists for the treatment of diabetes and obesity. He is identified as a top-five translation researcher by Nature Biotechnology for the years 2014 and 2015.
Dr. DiMarchi is the recipient of numerous awards including the 2005 AAPS Career Research Achievement Award in Biotechnology; the 2006 ACS Barnes Award for Leadership in Chemical Research Management; the 2006 ACS Esselen Award for Chemistry in the Service of Public Interest; the 2007 Carothers Award for Excellence in Polymer Sciences; the 2009 Watanabe Award for Life Sciences Research; the 2011 Merrifield Award for Career Contributions in Peptide Sciences; the 2014 German National Erwin Schrödinger-Preis, the 2015 Meienhofer Prize; 2015 Max Bergmann Medal and the 2016 ACS Alfred Burger Career Award in Medicinal Chemistry. He was inducted into the National Inventors Hall of Fame in 2014 and the National Academy of Medicine in 2015.
Soumitra Ghosh, Ph.D.President, Doon Associates LLC
Soumitra Ghosh is a biopharmaceutical industry consultant and entrepreneur with extensive experience in drug development, technology licensing and in formulating and implementing R&D strategy. He is a co-founder of Avexegen Therapeutics, Abvance Therapeutics and Aquros Bio, start-ups focused on GI indications, diabetes and urological disorders, respectively. His experience includes R&D leadership positions at Amylin Pharmaceuticals and MitoKor, where he led research programs for the development of small molecule, peptide and protein-based drug candidates for the treatment of metabolic diseases and CNS disorders. Multiple drug candidates were advanced to the clinic during his tenure, or were partnered with companies for clinical development. He has been a recipient of several SBIR and California state grants for his work in the industry. He received his MS and Ph.D. degrees in Chemistry from the Indian Institute of Technology and the University of Chicago, and conducted his post-doctoral work at the Rockefeller University in New York.
Fa Liu, Ph.D.Director of Chemistry, Novo Nordisk
Dr. Liu is the Director of Chemistry at Novo Nordisk Research Center, where he is leading the chemistry department to drive the peptide and protein therapeutics discovery targeting obesity, diabetes and other metabolic diseases. Prior to joining Novo, he was the Director of Chemistry at Calibrium Biotech where he played instrumental roles in building up the company portfolio (2014-2015). Dr. Liu started his industrial career at Eli Lilly (2009-2014) where he led the peptide lead optimization efforts across various disease areas and the establishment of novel insulin chemistries. He has advanced significant number of discovery programs including two into clinical trials and many into preclinical development. Dr. Liu has published more than 60 scientific articles and patents.
Dr. Liu received his Ph.D. from the Shanghai Institute of Organic Chemistry in 2004 followed by a five year stay at the National Cancer Institute as a postdoctoral fellow (2004-2007) and a staff scientist (2007-2009).
Andrew Parker Ph.D., MBACSO and SVP, Head of Research & External Innovation, Zealand Pharma
Andrew Parker joined Zealand in July 2016. Prior to this Andrew was a General Partner and Scientific Director for the Life Sciences Investment Fund Eclosion2 &; Cie SCPC in Switzerland. In parallel, he held the position of CEO for Arisgen SA (an Eclosion2 portfolio company developing an oral peptide drug delivery technology).
Mr. Pankaj R. PatelChairman and Managing Director, Cadila Healthcare Limited
Mr. Pankaj Patel has been the guiding force behind the Zydus Cadila’s fast tracked growth. With an experience spanning over 30 years in the Indian pharmaceutical industry, Mr. Patel combines both research and techno-commercial expertise and has published 50 research papers. Mr. Patel is on the governing councils of many national industry associations. He is a member of the Advisory council for developing Human Resources for the Pharma Industry, and is also a part of the Task force on R&D and Drug Discovery, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. Mr. Patel is also an industry representative for the ‘Consultative Group on Exports of Pharmaceutical Products’ under the Chairmanship of the Minister for Commerce and Industry, Government of India. Mr. Patel is currently the President of the Indian Pharmaceutical Alliance and the Chairman of the Federation of Indian Chamber of Commerce & Industry (FICCI) Gujarat State Council. He is the Executive Chairman, Vice President and Trustee of the Gujarat Cancer Society and Chairman of the Gujarat Cancer and Research Institute. Mr. Patel is also on the Governing Board of The Ahmedabad University and the President of the Ahmedabad Management Association. Mr. Patel was awarded the E&Y Entrepreneur of the Year – Life Sciences Award for the year 2009, the M.L. Schroff Memorial National Award in 2009 and the ‘Baroda Sun Lifetime Achievement Award’ for the year 2010 by the Bank of Baroda. Recently, Mr. Pankaj Patel was conferred the Indian Pharmaceutical Association’s ‘Special Recognition Award 2010’ in recognition of his contributions to the growth of the Pharmaceutical Industry, Research and the Profession of Pharmacy.
Claudio D. Schteingart, Ph.D.Vice President, Science & Technology, Ferring Research Institute, Inc.
Dr. Schteingart is Vice President, Science & Technology – Research at Ferring Research Institute Inc. His current responsibilities are the evaluation of new technologies for the discovery and development of novel peptide therapeutics and to provide guidance to drug discovery programs at the Institute as well as supporting drug candidates in Development at Ferring Pharmaceuticals. He joined the Institute in 1996 as a research chemist and participated in the discovery of the peptidic GnRH antagonist degarelix, launched in 2009, and many other peptidic drug candidates in various stages of clinical development for women’s health, critical care medicine, and gastroenterology.
Dr. Schteingart received a Ph.D. in Chemistry at the University of Buenos Aires, Argentina. After postdoctoral studies in the Department of Chemistry at the University of California, San Diego, he moved to the Department of Medicine where he carried out research in the chemistry, physiology, metabolism, and physicochemical properties of biliary components and lipids.
Aleksander SwietlowGlobal Director, Quality Control, PolyPeptide Group
Aleksander Swietlow is an analytical chemist with over 20 years of experience in the pharmaceutical and biopharmaceutical industry. He is currently with the PolyPeptide Group, a multinational company specializing in contract manufacture of peptides, where he is responsible for quality control of peptide active pharmaceutical ingredients. Prior to joining PolyPeptide Group he was with Amgen for 10 years, where he lead a team responsible for developing analytical methods and supporting manufacturing development of peptides and other modalities. During his time at Amgen, Aleksander has been involved in a wide range of projects spanning small molecules, polymers, peptides through large recombinant proteins and complex molecules consisting of combinations of the above. Prior to Amgen, Aleksander was at PolyPeptide Laboratories, Inc. (6 years at the Torrance, California facility and 2 years at the Limhamn facility in Sweden), where he worked extensively with development and validation of analytical methods for peptide characterization. He also gained experience with small molecule pharmaceutics at Pharmacia and Upjohn (now Pfizer), where he managed the Quality Control laboratory for 3 years.
Aleksander received his Ph.D. in Analytical Chemistry at the University of Lund (Sweden), followed by postdoctoral studies at the Johannes Gutenberg University in Mainz (Germany) and a fellowship at the Max Planck Institute for Polymer Studies in Mainz. In addition to professional activities Aleksander also performed volunteer work for the United States Pharmacopeia (USP), where he served on the Peptide Therapeutics Expert Panel (2012 – 2015) and also on Peptides and Insulins Expert Committee (2015-2016).
Stéphane Bolduc – CHU de Québec – Université Laval Research Center
Marcello Costa – Flinders University
Warren Foster – University of California, San Diego
Andrew Horne – University of Edinburgh
K. Joseph Hurt – University of Colorado
Ursula Kaiser – Brigham and Women’s Hospital, Harvard Medical School
Sarah Marshall – Monash University
Kathryn Meier – Washington State University
Victor Navarro – Brigham and Women’s Hospital, Harvard Medical School
Willis Samson – Saint Louis University, School of Medicine
John Taylor – Kansas University Medical Center
Suraj Unniappan – University of Saskatchewan
Henrique Veiga-Fernandes – Champalimaud Foundation
Meet the 2016 Recipients
October 25-26, 2018
The Salk Institute